» Authors » Wim E Hennink

Wim E Hennink

Explore the profile of Wim E Hennink including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 428
Citations 9245
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
21.
Hernandez I, Grinwis G, Di Maggio A, Van Bergen en Henegouwen P, Hennink W, Teske E, et al.
Nanophotonics . 2022 Nov; 10(12):3075-3087. PMID: 36405501
Nanobody-targeted photodynamic therapy (NB-PDT) has been developed as a potent and tumor-selective treatment, using nanobodies (NBs) to deliver a photosensitizer (PS) specifically to cancer cells. Upon local light application, reactive...
22.
Rijcken C, De Lorenzi F, Biancacci I, Hanssen R, Thewissen M, Hu Q, et al.
Adv Drug Deliv Rev . 2022 Nov; 191:114613. PMID: 36343757
Nanomedicines are used to improve the efficacy and safety of pharmacotherapeutic interventions. Unraveling the biological behavior of nanomedicines, including their biodistribution and target site accumulation, is essential to establish design...
23.
van Nostrum C, Lammers T, Hennink W
Int J Pharm . 2022 Sep; 626:122147. PMID: 36058772
No abstract available.
24.
Hebels E, Bindt F, Walther J, van Geijn M, Weterings J, Hu Q, et al.
Biomacromolecules . 2022 Aug; 24(10):4385-4396. PMID: 36044412
Polymeric micelles (PMs) are promising platforms for enhanced tissue targeting of entrapped therapeutic agents. Strategies to circumvent premature release of entrapped drugs include cross-linking of the micellar core as well...
25.
Timmers M, Weterings J, van Geijn M, Bell R, Lenting P, Rijcken C, et al.
Bioconjug Chem . 2022 Aug; 33(9):1707-1715. PMID: 35979909
Core-cross-linked polymeric micelles (CCPMs) are a promising nanoparticle platform due to favorable properties such as their long circulation and tumor disposition exploiting the enhanced permeability and retention (EPR) effect. Sustained...
26.
Bagheri M, van Nostrum C, Kok R, Storm G, Hennink W, Heger M
Mol Pharm . 2022 Aug; 19(9):3057-3074. PMID: 35973068
Curcumin nanoformulations for intravenous injection have been developed to offset poor absorption, biotransformation, degradation, and excessive clearance associated with parenteral delivery. This review investigates (1) whether intravenous nanoformulations improve curcumin...
27.
Wang Y, Fens M, van Kronenburg N, Shi Y, Lammers T, Heger M, et al.
J Control Release . 2022 Aug; 349:954-962. PMID: 35931210
To improve the reliability of in vitro release studies of drug delivery systems, we developed a novel in vitro method for the evaluation of drug release from polymeric micelles in...
28.
Ilochonwu B, Mihajlovic M, Maas-Bakker R, Rousou C, Tang M, Chen M, et al.
Biomacromolecules . 2022 Jun; 23(7):2914-2929. PMID: 35735135
Retinal diseases are the leading cause of visual impairment worldwide. The effectiveness of antibodies for the treatment of retinal diseases has been demonstrated. Despite the clinical success, achieving sufficiently high...
29.
Lau C, Benne N, Lou B, Zharkova O, Ting H, Ter Braake D, et al.
J Control Release . 2022 Jun; 348:938-950. PMID: 35732251
The therapeutic potential of antigen-specific regulatory T cells (Treg) has been extensively explored, leading to the development of several tolerogenic vaccines. Dexamethasone-antigen conjugates represent a prominent class of tolerogenic vaccines...
30.
Louage B, van Steenbergen M, Nuhn L, Risseeuw M, Karalic I, Winne J, et al.
ACS Macro Lett . 2022 Jun; 6(3):272-276. PMID: 35650901
Acid-sensitive paclitaxel (PTX)-polymer conjugates were designed by applying a grafting-from-drug RAFT approach. PTX was linked through either a cyclic or a linear, acid-sensitive acetal moiety. Relative to direct esterification of...